Is it possible to predict the course of Dupuytren’s in an individual? Who will need surgery? Who will have rapid progression or an early recurrence after surgery and who won’t? Family and personal history provide general trends, but that’s all. Several studies have correlated the cellularity of nodule tissue and the presence of myofibroblasts with the risk for recurrence or “aggressive” Dupuytren’s. This study found in addition, alpha smooth muscle antigen and the MK167 gene related Ki-67 protein correlated with aggressive disease, the markers for tenascin and factor XIIIa less so. Unfortunately, these differences were a matter of degree, not absolute. What are the actual pieces of this puzzle? http://www.dupuytrenfoundation.org/DupPDFs/2005_Forsman_1055.pdf
Comments are closed.